LivaNova

UK-based Livanova was born of a combination between Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, Livanova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.

Nuovo farmaco promette di perdere peso in sole 4 settimane

Analyst Color

Long Ideas

Initiation

Analyst Ratings

Trading Ideas

LIVN

LivaNova gets Buy rating from Goldman Sachs analyst. $65 PT. The company appears poised for consistent revenue growth in its base business.

LivaNova&#39;s New Strategy Could Unlock Revenue, Profit Gains, Analyst Predicts

movers image

News

Intraday Update

Markets

Movers

ABNB

CURV

DCOM

GEVO

SNBR

TALK

TDOC

Compass Minerals, Torrid Holdings, Icahn Enterprises, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday

xr:d:DAFlJKNXbrw:2,j:4527636209394207909,t:23060712

AEMD

AIRJ

AONC

ASNS

ASST

BASE

BNRG

CHSN

CLEU

CODX

FDMT

FIVE

FRES

FRGT

GIII

HALO

ISPC

JWEL

KITT

LULU

MITQ

MSGM

NDRA

OLLI

ONMD

PHAR

PLTN

PXDT

REPL

RYDE

SCWX

SMAR

TRSG

UNFI

VIRI

VNDA

VRAX

VTYX

XPOF

ZCAR

Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

LivaNova PLC

Press Releases

LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting

RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients with Treatment-Resistant Depression

LivaNova Appoints Natalia Kozmina as Chief Human Resources Officer

LivaNova to Announce Fourth-Quarter and Full-Year 2024 Results

LivaNova to Present at the Barclays Global Healthcare Conference

LivaNova Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Guidance

LivaNova to Announce First-Quarter 2025 Results

LivaNova Announces 12-month Data from OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea, Demonstrating Strong Response and Durability of Therapy

Comments

LivaNova

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell